Indication intelligence, analysis and sector perception

RegMed Investors’ (RMi): Ready, aim, clear the estimates and forecast firing range, earnings release are set to light-up and down size the sector

November 3, 2019 2:45pm

Fate Therapeutics (FATE), Vericel (VCEL), Regenxbio (RGNX) and Ultragenyx (RARE) on 11/5;

AxoGen (AXGN), Athersys (ATHX), Ionis Pharmaceuticals (IONS), Sangamo Therapeutics (SGMO), Voyager Therapeutics (VYGR), Bellicum Pharmaceuticals (BLCM) and Caladrius Biosciences (CLBS) on 11/6;

Adverum Biotechnologies (ADVM), Audentes Therapeutics (BOLD) and Cellectis (CLLS) and Stemline Therapeutics (STML) on 11/7

…. and Biostage (BSTG) , BioLife Solutions (BLFS), and Applied Genetic Technologies (AGTC) on 10/12

Be ready … SELL the highs, wait for new bottoms or just HOLD for the temporary slide!

Look for guidance to the short and near-term future and the ability to “TRUST” the CEO as well as a strong “runway” but, be on the outlook for those who anticipate … accessing the capital markets.

Its’s dangerous to be so fragile until NEXT YEAR 2020 with current share pricing!

It’s reality training and re-education time!

35 companies, 1 interpreter!

Insight, foresight and recommendation

What's Happening Today

6 hours 51 min ago
RegMed Investors (RMi) Closing Bell: this week’s trend is an admission that the sector is without pricing sustainability suppressing a value directional

15 hours 53 min ago
RegMed Investors’ (RMi) pre-open: the down draft doesn’t seem to be over

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.